Applied Digital Reports Fiscal Second Quarter 2026 Results DALLAS, Jan. 07, 2026 (GLOBE NEWSWIRE) --...
Fiscal
Cancer Immunotherapy, LYMPHIR™, launched in the U.S. in December 2025 Completed $36 million in strategic financings, of which $18 million...
Management to hold webcast today at 5:00 pm Eastern New York, N.Y., Dec. 18, 2025 (GLOBE NEWSWIRE) -- NANO Nuclear...
NANO Nuclear Energy Inc. NANO Nuclear Energy Inc. NANO Nuclear Reports Fiscal Year 2025 Financial Results and Provides Business Update...
- Dosing is underway in the Phase 3 CYB003 PARADIGM program which comprises two 12-week randomized, double-blind, placebo-controlled studies (APPROACH™...
Sold approximately 120,000 Nu.Q® Vet Cancer Tests in 2024. Expanded access to the Nu.Q® Vet Cancer Test – now available for...
